drugset / Trial / NCT01536392

Oral Ondansetron Versus Transdermal Granisetron (Sancuso) for Women With Cervical, Endometrial or Vaginal Cancer Receiving Pelvic Chemoradiation

NCT01536392

Phase 3 Completed 76 enrolled M.D. Anderson Cancer Center Sancuso · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to compare granisetron (when given through a patch) to ondansetron (when taken by mouth) for reducing nausea and vomiting in women with cervical, endometrial, or vaginal cancer having chemoradiation. Granisetron and ondansetron are designed to help reduce nausea and vomiting.

Timeline

Start
2012-03
Primary completion
2019-10-03
Completion
2019-10-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Granisetron Other / unclassified 34.3 mg Other
Subject Ondansetron Other / unclassified 8 mg Oral

Indications